Supply Agreements — Royalty Income
Bristol-Myers Squibb Supply Agreements — Royalty Income remained flat by 0.0% to $300.00M in Q4 2024 compared to the prior quarter. Year-over-year, this metric grew by 25.0%, from $240.00M to $300.00M. Over 3 years (FY 2021 to FY 2024), Supply Agreements — Royalty Income shows an upward trend with a 18.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests successful monetization of the company's drug portfolio through external partnerships, while a decrease may indicate expiring patents or reduced demand for licensed technologies.
Detailed definition
This metric represents the revenue generated from licensing intellectual property and providing supply chain support to...
Peer comparison
Similar to royalty and licensing revenue reported by other large-cap pharmaceutical firms, which often derive value from out-licensing non-core assets or collaborative development agreements.
bmy_segment_supply_agreements_royalty_incomeHistorical Data
| FY'21 | FY'22 | FY'23 | FY'24 | |
|---|---|---|---|---|
| Value | $725.00M | $924.00M | $960.00M | $1.20B |
| YoY Change | — | +27.4% | +3.9% | +25.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's supply agreements — royalty income?
- Bristol-Myers Squibb (BMY) reported supply agreements — royalty income of $300.00M in Q4 2024.
- How has Bristol-Myers Squibb's supply agreements — royalty income changed year-over-year?
- Bristol-Myers Squibb's supply agreements — royalty income increased by 25.0% year-over-year, from $240.00M to $300.00M.
- What is the long-term trend for Bristol-Myers Squibb's supply agreements — royalty income?
- Over 3 years (2021 to 2024), Bristol-Myers Squibb's supply agreements — royalty income has grown at a 18.3% compound annual growth rate (CAGR), from $725.00M to $1.20B.
- What does supply agreements — royalty income mean?
- Revenue earned from licensing intellectual property and supplying products to third-party partners.